One Year of Weedcoin and the Cannabis Movement That Showed Up Every Day

The Weedcoin Team

365 days. 365 drops. One community. The anniversary is not the finish line. It is proof of concept.

One year ago today, Weedcoin launched on Solana. No venture capital. No celebrity endorsement. No roadmap full of promises that would never ship. Just a token, a tagline, and a bet that the cannabis community deserved something built with real content, real research, and real consistency.

Three hundred and sixty-five days later, the bet is paying off. Not in hype cycles or pump-and-dump charts, but in something harder to fake: a daily content operation that has not missed a single day. Every morning, research. Every morning, a blog. Every morning, images, captions, video, and conversation about where cannabis policy, science, and culture are actually heading.

That is what one year looks like. And it is only the beginning.

What Changed in a Year

When Weedcoin launched on April 1, 2025, the cannabis landscape looked different. Trump had not yet signed his executive order directing the attorney general to reschedule marijuana. The FDA had not submitted its first CBD enforcement policy. Medicare covering cannabis products was not even a conversation. The Army had not dropped its marijuana waiver requirement. Texas had not yet banned hemp flower. Idaho was not on the verge of putting medical cannabis on the ballot.

In twelve months, every one of those things happened.

The rescheduling process is underway -- stalled by a DEA appeal, but moving. The FDA is building its first regulatory framework for CBD. Medicare's pilot program to cover hemp-derived CBD for seniors was set to launch this week, though prohibitionist groups have now filed a lawsuit to block it. The Army's new policy takes effect on 4/20. Texas cleared its hemp shelves yesterday. Idaho has collected enough signatures to approach ballot qualification.

Weedcoin did not cause any of that. But Weedcoin covered all of it. Every development, every contradiction, every step forward and every step back -- documented, analyzed, and delivered to the community before most people finished their morning coffee.

That is what showing up every day builds. Not just content. Context.

The Medicare CBD Lawsuit

Speaking of contradictions that never stop: prohibitionist organizations led by Smart Approaches to Marijuana filed a lawsuit this week to stop the CMS pilot program from taking effect. The program, backed by a December 2025 presidential executive order, would allow participating physicians to recommend hemp-derived CBD products to Medicare beneficiaries through Accountable Care Organizations, with up to $500 per patient per year in coverage.

The lawsuit argues that CMS is bypassing the FDA drug approval process by covering products that have not undergone formal clinical validation. Whether the court blocks the program or allows it to proceed will set a precedent for how the federal government treats cannabis-adjacent health products going forward.

For patients -- especially seniors dealing with chronic pain, inflammation, and nausea -- this is not an abstract legal fight. It is the difference between having access to a treatment their doctor believes could help and being told to wait another decade for a bureaucratic process to catch up with the science.

Texas: Day One of the New Reality

The Texas hemp ban is now in effect. As of yesterday, THCA flower, pre-rolled joints, live resin, and all smokable hemp products exceeding 0.3 percent total THC are illegal to sell in the state. Manufacturer fees sit at $10,000 per facility. Retail fees at $5,000. Fines of up to $10,000 per day for noncompliance.

The Texas Hemp Business Council is expected to file a legal challenge. The broader legal battle -- including the 2021 Delta-8 case headed to the Texas Supreme Court -- continues. But for now, the shelves are empty and the shops that could not absorb the new costs are closed.

Texas joins Ohio and soon New Jersey (April 13) in the growing list of states that have effectively shut down their hemp-derived THC markets. The federal Farm Bill ban in November could make the rest of the map look the same.

Close-up of an eye examination with green light testing for glaucoma and eye pressure

Cannabis and Glaucoma: What the Science Actually Shows

Today's cannabis benefits section covers glaucoma -- the leading cause of irreversible blindness affecting over four million Americans. This is one of the oldest areas of cannabis research, dating back to the 1970s, and the science tells a nuanced story.

Multiple clinical studies have confirmed that cannabinoids can reduce intraocular pressure, the key risk factor in glaucoma. Research reports IOP reductions ranging from 20 to 30 percent with various cannabinoid formulations. Approximately 60 to 65 percent of patients experience the pressure-lowering effect -- a response rate comparable to some FDA-approved first-line glaucoma medications.

The mechanism is direct and local: THC binds to CB1 receptors in the ciliary epithelial cells and trabecular meshwork of the eye, reducing aqueous humor production and enhancing outflow. This is not a secondary effect of getting high -- it is a specific interaction between the cannabinoid and the eye's own receptor system.

However, there is a significant limitation. The pressure-lowering effect lasts only three to four hours. To maintain stable IOP throughout a 24-hour day, a patient would need to use cannabis six to eight times daily -- which is impractical for most people and carries its own side effect burden.

Pre-clinical research published in 2025 showed that cannabinoids may also protect retinal neurons from inflammation and damage, suggesting potential neuroprotective benefits beyond simple pressure reduction. But this work is early-stage.

An important caution: CBD alone does not appear to lower eye pressure. A 2006 randomized, double-masked study found that sublingual CBD at 20mg had no effect on IOP, while 40mg CBD actually produced a transient pressure increase. Separate research in mice confirmed that CBD can interfere with THC's pressure-lowering effects.

The medical consensus is clear: cannabis is not a replacement for standard glaucoma treatment. The American Academy of Ophthalmology, the American Glaucoma Society, and the Canadian Ophthalmological Society all recommend against cannabis as a primary therapy. But for patients already using cannabis for other conditions, the IOP-lowering effect is real and worth discussing with their eye doctor -- particularly since the timing of cannabis use relative to eye pressure measurements can affect clinical readings.

The honest story on glaucoma is that cannabis opened the door to understanding how cannabinoid receptors in the eye work, but conventional treatments have evolved to be more effective, more convenient, and safer for long-term use. The research contribution matters even when the clinical application is limited.

Solana: Building From the Bottom

Solana enters April trading around $83, down from February highs near $90 but building higher lows from the $67 bottom. The broader crypto market remains under pressure from geopolitical volatility and a hawkish Fed hold, but Solana's on-chain fundamentals continue to show strength.

Key levels for April: $80 support remains critical. A break above $86 (the 20-day EMA) would signal short-term recovery toward $93. The Alpenglow consensus upgrade targeting 150-millisecond finality continues its rollout. Standard Chartered identified a shift in Solana revenue from meme coins to stablecoins -- a maturation signal that could reframe institutional perception of the network.

US spot SOL ETFs have accumulated nearly $1 billion in cumulative inflows, though the last few days saw modest outflows. The transition from speculative trading revenue to infrastructure-grade stablecoin settlement is exactly the kind of evolution that builds long-term value.

For Weedcoin, the network underneath us is getting stronger even when the price charts are messy. That is what you want from infrastructure.

Nineteen Days to 4/20

The countdown continues. Nineteen days until 4/20. Zero days until the anniversary.

One year of Weedcoin. One year of showing up. One year of proving that a cannabis project built on real content, real research, and real community can outlast the noise.

Like bitcoin but way higher.